Amneal expands portfolio with four new generics

BRIDGEWATER, N.J. — Amneal Pharmaceuticals announced four new additions to its portfolio of generic drugs, which represent multiple therapeutic categories and account for $900 million annually in U.S. sales, the company said, citing data from IMS Health.



The new generic products are:

• 
  Acyclovir ointment, USPL: Available in 5% strength and sold in 30-g. tubes. Each gram of ointment contains 50 mg of acyclovir. The Amneal generic is the therapeutic equivalent to Zovirax ointment 5%;


• 
  Atovaquone oral suspension, USP: The first-to-market generic is available in 750-mg/5-mL strength and comes packaged in 8-fl. oz. bottles. The drug is the therapeutic equivalent to Mepron oral suspension;


• 
  Clindamycin palmitate hydrochloride for oral solution, USP (dediatric): Available in 75 mg/5 mL reconstituted strength. Mixing the powder with water provides 100 mL of a clear, cherry-flavored solution. The Amneal product is the therapeutic equivalent to Cleocin Pediatric.


• 
  Oxycodone hydrochloride tablets, USP (C-II): Available in 5-mg, 10-mg, 15-mg, 20- mg or 30-mg strength in 100-count bottles. The Amneal generic is the equivalent to Roxicodone.

“Introducing these four products in the market aligns with our strategic focus on extending our generic offerings across all dosage forms,” said Chirag Patel, co-CEO and co-chairman of Amneal.  “Currently, we have 125 ANDAs filed with the U.S. FDA across numerous dosage forms, including transdermal, oral liquid, topical, injectable, oral solid, ophthalmic and otic.  These new medications will further diversify our expansive portfolio.”